If approved, AZN's Fasenra will be the second biologic approved in the European Union to treat eosinophilic granulomatosis ...

Daiichi Sankyo and AstraZeneca saw a dip in stock prices after announcing that their Phase III TROPION-Breast01 trial for ...

AstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast ...

This briefing covers notable health news: the US is donating 1 million mpox vaccine doses to Africa, AstraZeneca’s breast ...

Shares of Skye Bioscience gained after the San Diego biopharmaceutical company highlighted the safety of its in-development obesity treatment as compared with rivals. AstraZeneca shares slipped after ...

Analysis of the TROPION-Breast01 study showed that treatment with Dato-DXd did not significantly improve overall survival compared with chemotherapy in HR-positive, HER2-low or -negative breast cancer ...

Despite showing a progression-free survival benefit, the antibody-drug conjugate did not improve overall survival in HR-positive, HER2-negative or -low breast cancer.

Key updates in the health sector have emerged, with AstraZeneca facing disappointment in a breast cancer drug trial. The ...

PARIS: European shares closed higher on Monday as a soft business activity reading strengthened the case for more monetary ...

EUROPEAN shares closed higher on Monday as a soft business activity reading strengthened the case for more monetary policy ...

IDEAYA Bioscience’s rare cancer drug shows benefit in interim Phase II data, with the company announcing the drugs Phase III ...

Renal cancer, also known as kidney cancer, is a disease where malignant (cancer) cells form in the tissues of the kidneys. Smoking, obesity, hypertension, and chronic kidney disease contribute to ...